(VIANEWS) – BlackRock Capital Investment Corporation (BKCC), Stellus Capital Investment Corporation (SCM), New Mountain Finance Corporation (NMFC) are the highest payout ratio stocks on this list.
We have congregated information regarding stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. BlackRock Capital Investment Corporation (BKCC)
400% Payout Ratio
BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.
Earnings Per Share
As for profitability, BlackRock Capital Investment Corporation has a trailing twelve months EPS of $0.1.
PE Ratio
BlackRock Capital Investment Corporation has a trailing twelve months price to earnings ratio of 34.6. Meaning, the purchaser of the share is investing $34.6 for every dollar of annual earnings.
Sales Growth
BlackRock Capital Investment Corporation’s sales growth is 51.8% for the current quarter and 18.7% for the next.
Moving Average
BlackRock Capital Investment Corporation’s worth is higher than its 50-day moving average of $3.25 and below its 200-day moving average of $3.53.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 10% and a drop 7.7% for the next.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 11.56%.
2. Stellus Capital Investment Corporation (SCM)
174.59% Payout Ratio
Stellus Capital Investment Corporation is a business development company specializing in investments in private middle-market companies. It invests through first lien, second lien, unitranche, and mezzanine debt financing, often with a corresponding equity investment. The fund prefers to invest in US and Canada. The fund seeks to invest in companies with an EBITDA between $5 million and $50 million.
Earnings Per Share
As for profitability, Stellus Capital Investment Corporation has a trailing twelve months EPS of $0.71.
PE Ratio
Stellus Capital Investment Corporation has a trailing twelve months price to earnings ratio of 20.38. Meaning, the purchaser of the share is investing $20.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.95%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 11.21%.
3. New Mountain Finance Corporation (NMFC)
155% Payout Ratio
New Mountain Finance Corporation is a Business Development Company specializing in investments in middle market companies and debt securities at various levels of the capital structure, including first and second lien debt, unsecured notes, bonds, and mezzanine securities. It invests in various industries that include software, education, business services, distribution and logistics, federal services, healthcare services and products, healthcare facilities, energy, media, consumer and industrial services, healthcare Information Technology, Information Technology and services, specialty chemicals and materials, telecommunication, retail, and power generation. It seeks to invest in United States. It typically invests between $10 million and $50 million. Within middle market it seeks to invest in companies having EBITDA between $20 million and $200 million. It prefers to invest in equity interests, such as preferred stock, common stock, warrants, or options received in connection with its debt investments and directly in the equity of private companies. The fund makes investments through both primary originations and open-market secondary purchases. It invests primarily in debt securities that are rated below investment grade and have contractual unlevered returns of 10% to 15%. The firm may also invest in distressed debt and related opportunities and prefers to invest in targets having private equity sponsorship. It seeks to hold its investments between five years and ten years. The fund prefer to have majority stake in companies.
Earnings Per Share
As for profitability, New Mountain Finance Corporation has a trailing twelve months EPS of $0.8.
PE Ratio
New Mountain Finance Corporation has a trailing twelve months price to earnings ratio of 15.65. Meaning, the purchaser of the share is investing $15.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.08%.
Yearly Top and Bottom Value
New Mountain Finance Corporation’s stock is valued at $12.52 at 08:23 EST, under its 52-week high of $13.59 and way higher than its 52-week low of $11.17.
4. Rexford Industrial Realty (REXR)
139.47% Payout Ratio
Rexford Industrial, a real estate investment trust focused on owning and operating industrial properties throughout Southern California infill markets, owns 232 properties with approximately 27.9 million rentable square feet and manages an additional 20 properties with approximately 1.0 million rentable square feet.
Earnings Per Share
As for profitability, Rexford Industrial Realty has a trailing twelve months EPS of $0.95.
PE Ratio
Rexford Industrial Realty has a trailing twelve months price to earnings ratio of 57.59. Meaning, the purchaser of the share is investing $57.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.96%.
Yearly Top and Bottom Value
Rexford Industrial Realty’s stock is valued at $54.71 at 08:23 EST, way below its 52-week high of $68.68 and way higher than its 52-week low of $48.74.
Volume
Today’s last reported volume for Rexford Industrial Realty is 342009 which is 81.62% below its average volume of 1861060.
5. Bristol (BMY)
64.72% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.43.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 17.82. Meaning, the purchaser of the share is investing $17.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.07%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2.7%, now sitting on 45.85B for the twelve trailing months.
Previous days news about Bristol (BMY)
- Bristol-myers (bmy) to report Q2 earnings: what's in store?. According to Zacks on Tuesday, 25 July, "Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote"
- : bristol myers stock takes a hit from earnings miss and lower outlook amid disappointing revlimid sales. According to MarketWatch on Thursday, 27 July, "Shares of Bristol Myers Squibb Co. shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. "
- Compared to estimates, bristol myers (bmy) Q2 earnings: A look at key metrics. According to Zacks on Thursday, 27 July, "Here is how Bristol Myers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
- Bristol-myers (bmy) Q2 earnings, sales miss, '23 view lowered. According to Zacks on Thursday, 27 July, "Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote"
6. Verizon (VZ)
50.54% Payout Ratio
Verizon Communications Inc., through its subsidiaries, provides communications, technology, information, and entertainment products and services to consumers, businesses, and governmental entities worldwide. It operates in two segments, Verizon Consumer Group (Consumer) and Verizon Business Group (Business). The Consumer segment provides wireless services across the wireless networks in the United States under the Verizon and TracFone brands and through wholesale and other arrangements; and fixed wireless access (FWA) broadband through its wireless networks. It also offers wireline services in the Mid-Atlantic and Northeastern United States, as well as Washington D.C. through its fiber-optic network, Verizon Fios product portfolio, and a copper-based network. The Business segment provides wireless and wireline communications services and products, including data, video, conferencing, corporate networking, security and managed network, local and long-distance voice, network access, and various IoT services and products, as well as FWA broadband through its wireless networks. The company was formerly known as Bell Atlantic Corporation and changed its name to Verizon Communications Inc. in June 2000. Verizon Communications Inc. was incorporated in 1983 and is headquartered in New York, New York.
Will nothing but upside for high-yield verizon?The price action in Verizon (NYSE:VZ) stock has been trying hard to put in a bottom, and the factors supporting the move are still in place. , The analysts and institutional activity suggest that the sell-side is interested in Verizon for these reasons.
Earnings Per Share
As for profitability, Verizon has a trailing twelve months EPS of $5.
PE Ratio
Verizon has a trailing twelve months price to earnings ratio of 6.77. Meaning, the purchaser of the share is investing $6.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.59%.
Previous days news about Verizon (VZ)
- Verizon (vz) beats Q2 earnings estimates, falters on revenues. According to Zacks on Tuesday, 25 July, "Verizon Communications Inc. price-eps-surprise | Verizon Communications Inc. Quote", "However, Verizon registered 69,000 Fios Video net losses in the quarter, reflecting the ongoing shift from traditional linear video to over-the-top offerings."
- According to Zacks on Tuesday, 25 July, "So the positive pre-market is a long time coming; Verizon remains near multi-year lows."
- According to Zacks on Tuesday, 25 July, "So the positive pre-market is a long time coming; Verizon remains near multi-year lows."
- According to FXStreet on Wednesday, 26 July, "The Dow jumped 0.52% on Monday but barely budged on Tuesday following mixed earnings results from components Verizon (VZ) and Visa (V).", "Tuesday, July 25 – Microsoft (MSFT) beats on top and bottom lines, Visa (V) misses on GAAP EPS but beats revenue consensus, Verizon (VZ) misses both GAAP EPS and revenue forecast"
